Functional systemic CD 4 immunity is required for clinical responses to PD ‐L1/PD ‐1 blockade therapy

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Bibliographic citation: Functional systemic CD 4 immunity is required for clinical responses to PD ‐L1/PD ‐1 blockade therapy ; volume:11 ; number:7 ; year:2019 ; extent:14
EMBO molecular medicine / European Molecular Biology Organization ; 11, Heft 7 (2019) (gesamt 14)

Creator: Zuazo, Miren
Arasanz, Hugo
Fernández‐Hinojal, Gonzalo
García‐Granda, Maria Jesus
Gato, María
Bocanegra, Ana
Martínez, Maite
Hernández, Berta
Teijeira, Lucía
Morilla, Idoia
Lecumberri, Maria Jose
Fernández de Lascoiti, Angela
Vera, Ruth
Kochan, Grazyna
Escors, David

DOI: 10.15252/emmm.201910293

URN: urn:nbn:de:101:1-2022072008491986129598

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:37 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Zuazo, Miren
Arasanz, Hugo
Fernández‐Hinojal, Gonzalo
García‐Granda, Maria Jesus
Gato, María
Bocanegra, Ana
Martínez, Maite
Hernández, Berta
Teijeira, Lucía
Morilla, Idoia
Lecumberri, Maria Jose
Fernández de Lascoiti, Angela
Vera, Ruth
Kochan, Grazyna
Escors, David

Other Objects (12)

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Cellular mechanisms of combining innate immunity activation with PD-1/PD-L1 blockade in treatment of colorectal cancer

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders

Metabolism/Immunity Dual‐Regulation Thermogels Potentiating Immunotherapy of Glioblastoma Through Lactate‐Excretion Inhibition and PD‐1/PD‐L1 Blockade

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Optimal Timing of PD-1/PD-L1 Blockade Protects Organ Function During Sepsis

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Manipulation of PD‐L1 Endosomal Trafficking Promotes Anticancer Immunity

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Cellular mechanisms of combining innate immunity activation with PD-1/PD-L1 blockade in treatment of colorectal cancer

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders

Metabolism/Immunity Dual‐Regulation Thermogels Potentiating Immunotherapy of Glioblastoma Through Lactate‐Excretion Inhibition and PD‐1/PD‐L1 Blockade

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Optimal Timing of PD-1/PD-L1 Blockade Protects Organ Function During Sepsis

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Manipulation of PD‐L1 Endosomal Trafficking Promotes Anticancer Immunity

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Cellular mechanisms of combining innate immunity activation with PD-1/PD-L1 blockade in treatment of colorectal cancer

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders

Metabolism/Immunity Dual‐Regulation Thermogels Potentiating Immunotherapy of Glioblastoma Through Lactate‐Excretion Inhibition and PD‐1/PD‐L1 Blockade

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Optimal Timing of PD-1/PD-L1 Blockade Protects Organ Function During Sepsis

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Manipulation of PD‐L1 Endosomal Trafficking Promotes Anticancer Immunity

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Functional systemic CD 4 immunity is required for clinical responses to PD ‐L1/PD ‐1 blockade therapy

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Cellular mechanisms of combining innate immunity activation with PD-1/PD-L1 blockade in treatment of colorectal cancer

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders

Metabolism/Immunity Dual‐Regulation Thermogels Potentiating Immunotherapy of Glioblastoma Through Lactate‐Excretion Inhibition and PD‐1/PD‐L1 Blockade

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Optimal Timing of PD-1/PD-L1 Blockade Protects Organ Function During Sepsis

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Manipulation of PD‐L1 Endosomal Trafficking Promotes Anticancer Immunity

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Cellular mechanisms of combining innate immunity activation with PD-1/PD-L1 blockade in treatment of colorectal cancer

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders

Metabolism/Immunity Dual‐Regulation Thermogels Potentiating Immunotherapy of Glioblastoma Through Lactate‐Excretion Inhibition and PD‐1/PD‐L1 Blockade

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Optimal Timing of PD-1/PD-L1 Blockade Protects Organ Function During Sepsis

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Manipulation of PD‐L1 Endosomal Trafficking Promotes Anticancer Immunity

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Cellular mechanisms of combining innate immunity activation with PD-1/PD-L1 blockade in treatment of colorectal cancer

Tumor cells versus host immune cells: whose PD-L1 contributes to PD-1/PD-L1 blockade mediated cancer immunotherapy?

Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders

Metabolism/Immunity Dual‐Regulation Thermogels Potentiating Immunotherapy of Glioblastoma Through Lactate‐Excretion Inhibition and PD‐1/PD‐L1 Blockade

Systemic CD4 immunity: A powerful clinical biomarker for PD‐L1/PD‐1 immunotherapy

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma

Optimal Timing of PD-1/PD-L1 Blockade Protects Organ Function During Sepsis

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Manipulation of PD‐L1 Endosomal Trafficking Promotes Anticancer Immunity

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response

Related objects

Reset password